Medical Watch Disease & Treatment News

Phage therapy is resurging as a key weapon against antibiotic-resistant superbugs, with biotechs advancing clinical candidates.

• Armata's AP-SA02:...

New findings reveal impaired autophagy and synaptic dysfunction as core shared mechanisms between autism spectrum disorder (ASD) and Alzheimer’s...

FDA's evolving frameworks signal a trend toward faster gene therapy approvals for rare diseases:

• Genome editing safety: Draft guidance mandates...

Microbiome breakthrough: Ewingella americana from amphibian guts fully eliminates colorectal tumors in 100% of mice after one IV dose, with no...

Rapid leap to Phase II after positive Phase I: XS411 iPSC-derived cells showed significant motor improvements (MDS-UPDRS OFF scores, ON time, QoL >...

Key breakthrough: Alzheimer's triggers microglia to prune healthy nerve fibers from locus coeruleus to olfactory bulb via phosphatidylserine "eat-me"...

• Game-changer: Texas A&M study reverses neuroinflammaging—chronic brain inflammation causing fog, memory issues, and Alzheimer’s risk—with a simple...

Key advance in DS therapy: Modified CRISPR-Cas9 inserts XIST gene onto trisomic chromosome 21, silencing it with 20-40% efficiency.

• Achieves...

FDA regulatory advances are accelerating treatments for lysosomal storage and neurodeg disorders:

• Avlayah approved for Hunter Syndrome, a rare...

Emerging evidence challenges uniform AD models with sex-specific paths:

• Women, 2/3 of patients, show faster metabolic decline and heavier tau via...

Emerging strategies target high-risk APOE carriers to slow Alzheimer's:

• APOE3 Christchurch variant limits tau spread, suppresses inflammation, and...

Game-changer ahead: Astrocyte-targeted CAR immunotherapy could enable a one-time, disease-modifying therapy applied early or preventively against...

Breakthrough PROGRESS framework uses a single baseline CSF assessment to predict Alzheimer's progression:

• Dual-model AI forecasts cognitive decline...

FDA Approvals

• 🔥 Filspari for Rare Kidney Disorder: FDA expanded label for Travere's Filspari, making it the first approved therapy for another...

pTau217 blood test predicts Alzheimer’s amyloid buildup in healthy adults, years before PET scans show signs.

• Studied 317 cognitively normal seniors...

FDA expands Filspari's label on Monday as the first US-approved therapy for a rare kidney disorder, adding another kidney condition to its indications.

Breakthrough for MPS-II kids: FDA grants accelerated approval to new drug for rare childhood dementia.

• Strikes around age 2, causing body-wide...

Phase 3 breakthrough: Daraxonrasib extended median survival to 13.2 months vs 6.7 months on chemo for pretreated metastatic pancreatic cancer.
-...

Boost vitamin D now for potential long-term brain protection: New study links higher midlife levels to lower tau tangles 16 years later.

Key findings...

Don't miss the Alzheimer's Association's free virtual event today:

• New advancements in treatments that slow disease progression
• Details on...